IL6R and uveitis: Anti-VEGF for DME/NPDR–PDR (80)(B); Steroids (DEX/FA implants) (19)(B); IL-6R blockade (tocilizumab) for refractory DME/uveitis overlap (clinical/phase trials) (81)(B); NLRP3 inhibition (exploratory) (82)(B)